Skip to content

Paclitaxel Protein Bound

    DEA Class; Rx

    Common Brand Names; Abraxane

    • Antineoplastics, Antimicrotubular

    Nanoparticle albumin-bound taxane; a microtubule inhibitor
    Used for metastatic breast cancer, locally advanced or metastatic NSCLC, and metastatic pancreatic cancer
    Do not start a new cycle if ANC is less than 1,500 cells/mm3; myelosuppression requires monitoring and possible adjustments in therapy

    Indicated for metastatic adenocarcinoma of the pancreas as first-line treatment in combination with gemcitabine

    Microtubule inhibitor indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy; prior therapy should have included an anthracycline unless contraindicated

    Indicated for locally advanced or metastatic non-small cell lung cancer (NSCLC), as first-line treatment in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy

    For the treatment of breast cancer.

    Neutrophils <1500 cells/mm³

    Documented hypersensitivity to drug or excipients

    • Alopecia (90%)
    • Neutropenia (<2 x 10^9/L) (80%)
    • Sensory neuropathy, any (71%)
    • Abnormal EKG, all patients (60%)
    • Asthenia (47%)
    • Myalgia/arthralgia (44%)
    • AST increased (39%)
    • Alkaline phosphatase increased (36%)
    • Abnormal EKG, patients normal at baseline (35%)
    • Anemia (<11 g/dL) (33%)
    • Nausea (30%)
    • Diarrhea (27%)
    • Infections (24%)
    • Vomiting (18%)
    • Dyspnea (12%)
    • NSCLC (47%)
    • Pancreatic cancer (38%)
    • Metastatic breast cancer (34%)

    Sepsis occurred in 5% of patients with or without neutropenia; biliary obstruction or presence of biliary stent were risk factors for severe or fatal sepsis; if a patient becomes febrile (regardless of ANC) initiate treatment with broad-spectrum antibiotics; for febrile neutropenia, interrupt this drug and gemcitabine until fever resolves and ANC ≥ 1500, then resume treatment at reduced dose levels

    Pneumonitis, including fatalities, occurred in 4% of patients; monitor patients for signs and symptoms of pneumonitis and interrupt this drug and gemcitabine during evaluation of suspected pneumonitis; after ruling out infectious etiology and upon making a diagnosis of pneumonitis, permanently discontinue treatment with this drug and gemcitabine

    Contains albumin (human), a derivative of human blood; based on effective donor screening and product manufacturing processes, it carries a remote risk for transmission of viral diseases; a theoretical risk for transmission of Creutzfeldt-Jakob Disease (CJD) also is considered extremely remote; no cases of transmission of viral diseases or CJD have ever been identified for albumin

    CYP3A4 and CYP2C8 substrate; inducers or inhibitors of these isoenzymes may alter metabolism; if coadministered, monitor closely

    Grade 3 peripheral neuropathy reported; no patients developed Grade 4 peripheral neuropathy; upon suspension of dosing, the median time to improvement from Grade 3 peripheral neuropathy to ≤ Grade 1 was 29 days; of paclitaxel-treated patients with Grade 3peripheral neuropathy, 44% resumed paclitaxel at a reduced dose; may require dose reduction or treatment interruption (see Dosage Modifications)

    Based on its mechanism of action and findings in animals, therapy can cause fetal harm when administered to a pregnant woman; there are no available human data to inform drug-associated risk

    There are no data on presence of drug in human milk, or effect on breastfed child or on milk production


    260 mg/m2 IV.


    260 mg/m2 IV.


    Safety and efficacy have not been established.


    Safety and efficacy have not been established.


    Safety and efficacy have not been established.


    Safety and efficacy have not been established.

    Paclitaxel protein bound

    injection, lyophilized powder for reconstitution

    • 100mg/vial